Major R&D Pipeline: 3ADCs
Revenue: Major Products in Japan
Daiichi-Sankyo
(Bn JPY)
FY2020 Q1
FY2021 Q1
YOY
Results
Results
Lixiana
anticoagulant
19.8
22.9
+3.1
Nexium
ulcer treatment
19.9
19.7
-0.2
treatment for osteoporosis/ inhibitor of the progression of
Pralia
8.7
9.2
+0.5
bone erosion associated with rheumatoid arthritis
Tarlige
pain treatment
4.3
7.1
+2.8
Tenelia
type 2 diabetes mellitus treatment
6.6
6.4
-0.2
Ranmark
treatment for bone complications caused by bone metastases
from tumors
5.0
5.1
+0.2
Loxonin
anti-inflammatory analgesic
6.2
5.8
-0.4
Vimpat
anti-epileptic agent
3.8
4.5
+0.7
Canalia
type 2 diabetes mellitus treatment
3.9
4.3
+0.4
Efient
antiplatelet agent
3.8
4.1
+0.3
anti-cancer agent
Enhertu
0.2
2.2
+2.0
(HER2-directed antibody drug conjugate)
Rezaltas
antihypertensive agent
3.6
3.3
-0.3
Inavir
anti-influenza agent
0.6
0.3
-0.3
9View entire presentation